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Abstract 
Background: According to Centers for Disease Control and Prevention (CDC) tuberculosis 
(TB) report TB case rate dropped from 3.2 to 3.0 per 100,000 person in 2013 in the U.S, which 
was a 4.3% decrease from 2012, but the proportion of total cases occurring in foreign-born 
persons reached to 65% of the national case total. This proportion has been increasing since 
1993. Studies found that progression of latent tuberculosis infection (LTBI) to active TB 
(reactivation TB) contributed a large proportion to TB cases among foreign-born persons and 
posed a huge challenge to TB elimination in the U.S. The Division of Global Migration and 
Quarantine (DGMQ) in CDC provides Tuberculosis Screening and Treatment Technical 
Instructions (TB TI) for U.S.-bound immigrant and refugee overseas medical screening. The 
2007 TB TI made several changes to enhance overseas medical screening for TB. One of them is 
requiring applicants aged 2-14 years who live in countries with a World Health Organization 
(WHO)-estimated TB incidence rate equal or higher than 20 cases per 100,000 population to 
have a tuberculin skin test (TST) or interferon gamma release assay (IGRA) to detect TB/LTBI.      
Objectives: To assess LTBI prevalence among immigrant and refugee children aged 2-14 years 
who arrived in the United States in 2008-2012 and to explore demographic and geographic 
predictors among LTBI cases. 
Methods: Using DGMQ data from 2008-2012, LTBI prevalence was calculated. Regression 
analyses were used to examine predictors of LTBI risk based upon geographic and select 
demographic characteristics (country of origin, sex, country-specific LTBI prevalence rate).   
Results: LTBI prevalence of all 199 immigrant and refugee arrival countries vs top 16 arrival 
countries were 6.30% and 8.76%, respectively. Top 16 arrival countries contributed to 68.40% 
arrivals but contributed to 95.08% of LTBI cases. LTBI prevalence of both populations showed 
an increasing trend in 2008-2012. The highest five prevalence countries were the Philippines 
(42.74%) Vietnam (9.35%), Mexico (8.71%), Bhutan (8.31%) and China (7.80%). Regression 
coefficient estimates (i.e., log odds) for country of origin predictor were significant (p<.0001) 
(all tests α = 0.05) for 14 out of 16 top arrival countries. Coefficient estimates for the predictors 
of female percentage, 2007 TB TI percentage, WHO TB prevalence, female less than 50 percent 
and its interaction with female percentage were all significant (p<.0001). 
Conclusions: Diagnosing and treating LTBI and continuing the battle against TB globally are 
critical to TB elimination in the U.S. 2007 TB TI has contributed to detecting LTBI cases, should 
be implemented vigorously in immigrant and refugee overseas medical screening. Receiving 
states should address their follow-up gaps to ensure the completion of TB/LTBI treatment. 
Resources need to be allocated properly to states with high TB/LTBI burden. 
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Chapter 1 
INTRODUCTION 
Background 
Tuberculosis and latent tuberculosis infection 
Tuberculosis (TB) is a serious infectious disease caused by a bacterium called Mycobacterium 
tuberculosis.  The bacteria mainly attack the lungs as well as other parts of the body.  Nodules 
(tubercles) grow in the tissues. TB can be fatal if left without proper treatment [1].    
 
TB is spread through the air when a person with TB sneezes, coughs, speaks, or sings.  People 
nearby may breathe in these bacteria and become infected [1]. 
 
TB bacteria can live asymptomatically in the body.  This is called latent TB infection (LTBI).  
Most of the people infected do not become sick because the body is able to fight the bacteria to 
stop them from growing.  People with LTBI have no symptoms and are not infectious, but if TB 
bacteria become active in the body and multiply, people with LTBI can progress to TB and 
become sick and infectious [1].  This is termed as reactivation TB [3] [4] [15]. 
 
TB and LTBI among foreign-born persons in the U.S. 
In 2013 in the U.S., the TB case rate dropped from 3.2 to 3.0 per 100,000 person, which was a 
4.3% decrease from 2012, but the proportion of total cases occurring in foreign-born persons 
reached to 65% of the national case total.  This proportion has been increasing since 1993.  TB 
case rate per 100,000 for U.S.-born persons and foreign-born persons were 1.2 and 15.6, 
respectively, indicating the rate for foreign-born persons was 13 times of that of U.S.-born 
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persons [2].  Studies found that reactivation TB contributed a large proportion to TB cases 
among foreign-born persons and posed a huge challenge to TB elimination in the U.S. [3] [4]. 
 
2007 Tuberculosis Screening and Treatment Technical Instructions 
Foreign persons who applying for U.S. immigration/refugee status are required to have an 
oversea medical examination conducted by local panel physicians approved by the U.S. 
Department of States.  The medical screening for TB is essential in the medical examination.  
The Division of Global Migration and Quarantine (DGMQ) in Centers for Disease Control and 
Prevention (CDC) provides Tuberculosis Screening and Treatment Technical Instructions (TB 
TI) for panel physicians to be used in U.S.-bound immigrant and refugee overseas TB screening.  
Due to the challenges in TB diagnosis, treatment and control the TB TI was designed as a 
guideline to panel physicians to help detect and treat TB among U.S.-bound immigrants and 
refugees and prevent the importation of TB into the U.S.  
 
2007 TB TI requires U.S.-bound immigrants and refugees aged 2-14 years living in countries 
with a World Health Organization (WHO)-estimated TB incidence rate equal or higher than 20 
cases per 100,000 population, or having contact with TB or symptoms of TB to have a tuberculin 
skin test (TST) or an interferon gamma release assay (IGRA) test to detect TB/LTBI and to 
determine the need for a chest radiograph.  
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Objectives 
To assess LTBI prevalence among immigrant and refugee children aged 2-14 years who arrived 
in the United States in 2008-2012 and to explore demographic and geographic predictors among 
LTBI cases. 
 
Study population 
The study population was immigrant and refugee children aged 2-14 years who arrived in the 
United States in 2008-2012.  The terms “arrival/arrivals/arrived” used through this study referred 
to New Arrivals of immigrants and refugees who entered the U.S. as lawful permanent residents 
(LPRs) or "green card" holders and might live and work permanently in the U.S.  The other 
component of LPRs was Adjustments of Status (AOS) who first entered the U.S. as 
nonimmigrants and became LPRs through adjustment of status.  Refugees also became LPRs 
through AOS, therefore were included in AOS [6] [7].  AOS (excluding refugees) overseas 
medical examination data are not available to CDC at present. 
 
In 2008-2012, on average, immigrant and refugee yearly arrivals were approximately 470,000 
and 67,000, respectively, immigrant yearly arrivals were about seven times of refugee yearly 
arrivals.  Immigrant and refugee combined yearly arrivals were approximately half million.  The 
yearly arrivals of immigrant and refugee children aged 2-14 years were approximately 88,000 
and 16,000, respectively, immigrant children’s yearly arrivals were about five times of refugee 
children’s yearly arrivals.  The combined yearly arrivals of immigrant and refugee children aged 
2-14 years were approximately 100,000.  Refugee children aged 2-14 years counted for about 
25% of the total refugee yearly arrivals and immigrant children aged 2-14 years counted for 
4 
 
 
about 19% of the total immigrant yearly arrivals.  The combined yearly arrivals of immigrant and 
refugee children aged 2-14 years counted for about 19% the combined immigrant and refugee 
yearly arrivals (Table 1). 
 
Table 1.  Immigrant and Refugee New Arrivals – Total and Aged 2-14 Years 
  refugee new arrivals   immigrant new arrivals   total new arrivals 
Year total 
age  
2-14 
age  
2-14 
(%)   total 
age  
2-14 
age  
2-14 
(%)   total 
age  
2-14 
age  
2-14 
(%) 
2008 64737 16924 26.14   458793 87875 19.15   523530 104799 20.02 
2009 79941 19940 24.94  466756 88032 18.86   546697 107972 19.75 
2010 71361 18158 25.45  494724 93012 18.8   566085 111170 19.64 
2011 51456 12658 24.6  466172 85978 18.44   517628 98636 19.06 
2012 66285 16263 24.53  481403 85307 17.72   547688 101570 18.55 
Grand 
Total 333780 83943 25.15  2367847 440204 18.59   2701627 524147 19.4 
mean 66756 16788.6 25.13   473569 88040.8 18.6   540325 104829 19.4 
 
Institutional Review Board (IRB) approval 
This study was approved by the CDC/DGMQ and Georgia State University IRB for use of 
secondary and aggregate data sources pertinent to study objectives.  Detailed descriptions about 
the data sources were presented in Chapter 3.   
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Chapter 2 
REVIEW OF THE LITERATURE 
TB and LTBI are two related conditions 
TB and LTBI are related.  They both are caused by Mycobacterium tuberculosis bacterium; 
persons with LTBI get infected by persons with TB and may develop TB later on in their lives 
and the initial test for TB and LTBI are same [8] [9]. 
    
TST or IGRA are two kinds of tests that are used to determine if a person has TB infection.  TST 
performs an injection of a small amount of tuberculin extracted from TB bacteria and measures 
the size of the swelling in the injection area on the arm.  IRGA is a blood test and examines a 
person’s immune system reaction to TB bacteria [9].  
 
A negative test indicates that TB or LTBI is not likely.  A positive test indicates that a person has 
TB infection.  It cannot tell whether the person has LTBI or TB.  A chest radiograph is needed to 
determine.  If the determination still cannot be made, test of sputum smears or both sputum 
smears and culture are needed [1] [7].  If no signs and symptoms of TB found, then TB can be 
ruled out and the person with positive test has LTBI, otherwise, that person has TB [8] [9] [5]. 
  
TB is a global burden 
TB is deemed as a global burden by WHO [8].  It is the second greatest killer after HIV/AIDS 
among the infectious diseases worldwide.  In 2013, 9 million people became ill with TB and 1.5 
million died of TB.  550,000 children fell ill and 80,000 HIV-negative children died from TB.  It 
is the leading cause of death for HIV-positive people and women aged 15 to 44 years.  In regard 
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to geographic distribution of TB low and middle-income countries accounted for over 95% of 
TB deaths.  While a quarter of all TB cases occurred in Africa ranking it as the highest TB case 
rate per capita, half of all new cases occurred in six Asian countries including Bangladesh, 
China, India, Indonesia, Pakistan and the Philippines.  425,000 new multidrug-resistant TB 
(MDR-TB) occurred with the highest rates in the former USSR and China [10] [11].     
 
Prevalence of LTBI 
WHO estimates one-third of the world’s population, approximately 2 billion people have LTBI 
[[12] [13]. 
 
A symposium sponsored by WHO on management of LTBI pointed out “Latent TB infection 
(LTBI) is responsible for most TB cases in low incidence countries.  Reactivation TB 
significantly contributes to transmission in high burden countries” [14]. 
 
Reactivation TB  
According to a CDC estimate, overall, if no treatment, about 5 to 10% of persons with LTBI will 
have reactivation TB at some time in their lives, and about half of those with reactivation TB will 
experience it within the first two years of infection.  Persons with HIV infection have 
considerably higher risk of reactivation TB than those with normal immune systems [8].  WHO 
has the same estimate and suggests that the majority have reactivation TB within the first five 
years of infection [12].  
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A study by Horsburgh reviewed published reports and obtained estimates of the risk of TB 
among persons with a positive TST, based on these data a model was built to estimate the 
lifetime risk of reactivation TB among persons with certain medical conditions.  The study found 
that the lifetime risk of reactivation TB was 20% or higher among most persons with a TST 
being 10 mm of induration or larger; among most persons with HIV infection, and among most 
persons with evidence of old, healed TB.  The lifetime risk of reactivation TB was between 10 
and 20% among most persons aged 35 years or younger with a TST being 15 mm of induration 
or larger and were receiving infliximab therapy; among most persons aged 35 years or younger 
with a TST being 15 mm of induration or larger and had a recent conversion of TST; and among 
children aged 5 years or younger with a TST being 10 mm of induration or larger.  The author 
suggested that persons with high risk of reactivation TB should be targeted for testing and full 
treatment [15].  
 
A cross-sectional study conducted by Ricks et al. used data of patients with an Mycobacterium 
tuberculosis isolate genotyped by the U.S. National TB Genotyping Service in 2005–2009.  This 
service is a surveillance system established by CDC in 2004 and genotypes at least one 
Mycobacterium tuberculosis complex isolate of each TB case in the U.S.  The study assumed 
that TB cases were reactivation TB if they were not included in a localized cluster of cases.  This 
study calculated the overall proportion of reactivation TB in the total foreign-born TB cases, and 
that for the 25 countries that contributed the largest proportions of reactivation TB.  The study 
found that foreign-born persons accounted for 60% of total TB cases; among these foreign-born 
TB cases 83.7% were attributed to reactivation TB; Bangladesh was the top one country of origin 
from which foreign-born persons in the U.S. had the highest proportion (97.6%) of reaction TB 
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contributed to TB cases, and followed by India (95.2%) and Burma (93.3%).  This study 
analyzed relations between reactivation TB represented by crude odds ratios and 95% confidence 
interval and select factors represented by the grouped data for age at arrival in the U.S., time 
interval between arrival in the U.S. and diagnosis of TB, and WHO estimates of TB incidence 
per 100,000 for the countries of origin.  The age groups were 14 years or younger, 15-24 years, 
25-44 years, 45-64 years, 65 year or older.  The study found that reactivation TB was positively 
associated with WHO TB incidence, age at arrival in the U.S. and negatively associated with 
time interval between arrival in the U.S. and diagnosis of TB.  The study suggested the strategies 
to control TB among foreign-born persons in the U.S. should focus on finding and treating LTBI 
and reducing TB globally [3].   
 
A cohort study done by Walter et al. linked preimmigration data of Filipino visa applicants aged 
15 years or older examined in a medical center in the Philippines from 2001 to 2009 to TB cases 
among Philippines-born persons reported to California TB Case Registry from January 2001 to 
2010.  Records were matched by last name, first name, date of birth, sex and year of 
examination.  The study defined LTBI reactivation (i.e., reactivation TB) as TB with a normal 
preimmigration examination and chest radiograph; imported TB as TB occurred no more than six 
months after arrival in the U.S. with an abnormal preimmigration chest radiography; and 
reactivation of inactive TB as TB occurred more than six months after arrival in the U.S. with an 
abnormal preimmigration chest radiography.  The study found that within 1 year of 
preimmigration examination the proportions of each above defined type of TB in total TB cases 
matched distributed as reactivation TB (6%), imported TB (85%) and reactivation of inactive TB 
(9%).  Within 2-9 years of preimmigration examination, the proportions distributed as 
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reactivation TB (76%), and reactivation of inactive TB (24%).  Because of the high risk of LTBI 
this study suggested revise current guideline to extend LTBI screening to more than five years 
after the U.S. arrival [4]. 
 
Marais et al. reviewed pre-chemotherapy literature, which they thought documented the natural 
history of TB in childhood.  Most of the studies reviewed defined children as aged less than 15 
years, adolescents as aged more than 10 years and primary infection as first time TB infection 
indicated by TST conversion.   They pointed out although in general pulmonary TB in childhood 
was often considered a benign condition due to little risk to the child and little risk of 
transmission to the community it could pose a high risk of fatality to the child and a high risk of 
transmission to the community if it occured in specific years of age in childhood.  According to 
them the natural history of TB demonstrated that the 1st high-risk period was under 2 years, in 
which children with primary infection frequently progressed to miliary TB or TB meningitis 
without significant symptoms.  Children aged 2 to 10 years with primary infection rarely 
developed serious disease and had persistent symptoms.  This gave an opportunity for clinical 
diagnosis.  The 2nd high-risk period was adolescence. Children aged over 10 with primary 
infection frequently progressed to adult-type TB.  They suggested early effective intervention for 
high-risk group to reduce the disease burden and transmission [16].  
 
Risk factors of LTBI 
CDC updated guidelines for using IGRA to detect TB/LTBI published in 2010 categorized risk 
factors for TB and reactivation TB in order to assist targeted testing and selection of persons who 
were likely to benefit from treatment for LTBI.  Persons at increased risk of LTBI included: 
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those with HIV infection; aged 4 years or younger; receiving immunosuppressive therapy; 
infected with Mycobacterium tuberculosis within the past 2 years; with a history of TB that was 
not treated or treated inadequately; with diseases including silicosis, diabetes mellitus, chronic 
renal failure, leukemia, lymphoma, or cancer of the head, neck, or lung; having had a 
gastrectomy or jejunoileal bypass; with body weight less than 90% of their ideal weight; 
smoking cigarette or abusing drugs or alcohol; and populations with low-income, inadequate 
access to medical care and an environment of increase incidence of TB [13].  
 
A case-control study conducted by Saiman et al. analyzed risk factors for LTBI among children 
in New York City.  According to the authors their study “is the largest published study of risk 
factors for LTBI in young children.”  Data were collected from 24 primary care clinics from 
September 1996 to December 1998.  96 cases and 192 controls were enrolled.  Case participants 
were children aged between 1 to 5 years with LTBI.  LTBI case was defined as TST being 10 
mm of induration or larger with a normal chest radiograph, and control was defined as TST 
being 0 mm of induration.  Questionnaires in English and Spanish were used to collect 
demographic and SES information. The demographic characteristics of the subjects were 51% 
male, 80% Hispanic, 9% black and mean age being 2.9 years.  Univariate analysis found no 
difference between case and control in gender, age, ethnicity/race and language spoken at home 
and in the proportion of household income less than $20,000.  Logistic Regression Analysis 
found that having contact with TB or a relative with positive TST, born in a foreign country, 
traveling to a foreign were predictive of LTBI.  Having Bacille Calmette-Guerin (BCG) vaccine 
for TB, consuming raw dairy products and exposed to persons with history of illicit drug use, 
homelessness, or incarceration were not predictive of LTBI.  The authors pointed out that their 
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study population had a high proportion of crowding, poverty, lower SES, although these 
variables were found to be associated with TB by studies, they were not predictive in this study 
due to case-control matched design being used for the study.  This study suggested targeted 
screening for LTBI should focus on communities with immigrants migrated from countries with 
high rates of TB and consider LTBI risk factors [17].   
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Chapter 3 
METHODS 
Data sets 
Two data sets 
1st data set included all immigrant and refugee children aged 2-14 years who arrived in the 
United States in 2008-2012.  The total number of subjects in the data set was 524,147 
(N=524,147); total number of countries was 199, and the total number of records was 895. 
 
2nd data set included immigrant and refugee children aged 2-14 years who arrived in the United 
States in 2008-2012 from top 16 arrival countries (ranking by combined immigrant and refugee 
arrivals in 2008-2012).  This was a subset of 1st data set.  The total number of subjects in the data 
set was 358,516 (N=358,516), and the total number of records was 80. 
 
How the two data sets were used 
1st data set was used to calculate LTBI prevalence of all arrival countries and to compare that 
with the top 16 arrival countries.  2st data set was used to calculate LTBI prevalence of the top 
16 arrival countries and to build logistic regress model to assess association between LTBI 
prevalence (i.e., LTBI/total arrivals) and potential risk factors including country of origin, female 
percentage, TB TI 2007 percentage and WHO TB prevalence. 
 
The reason why using 2nd data set for analyzing association was because the top 16 arrival 
countries contributed to 68.40% (358516/524147) arrivals and 95.08% (31418/ 33045) LTBI 
cases (Table 3, Table 4).   It was also because they had complete data while many other arrival 
countries had missing data in 2008-2012 study period.   
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Table 2. Immigrant and Refugee Children Aged 2-14 Years Who Arrived in the United States in 
2008-2012 from Top 16 Arrival Countries – Total Arrivals (in Descending Order)  
Immigrant 
Refugee 
Combined 
Arrival Rank 
Country  
of Origin 
Immigrant 
Refugee 
Combined 
Arrivals 
1 Mexico 73305 
2 
Dominican 
Republic 50405 
3 The Philippines 33446 
4 Burma 24987 
5 China 24271 
6 Iraq 22112 
7 Vietnam 19325 
8 Haiti 18873 
9 India 14392 
10 Jamaica 13402 
11 Bhutan 13331 
12 El Salvador 11671 
13 Pakistan 11269 
14 Bangladesh 10950 
15 Ethiopia 9414 
16 Somalia 7363 
 
 
Data sources 
U.S. Department of Homeland Security (DHS) immigration data 
Data of immigrant arrivals, gender, age, country of birth and type of admission status (New 
Arrival or AOS) were requested and received by DGMQ from DHS.  They were not publically 
available.  Yearbook of Immigration Statistics published by DHS, which is publically available, 
does not contain data for Lawful Permanent Residents (LRPs) breakdown by New Arrivals and 
Adjustment of Status (AOS), and breakdown by country and birth for New Arrivals.  It also does 
not contain data for calendar year (only for U.S. federal fiscal year October 1 to September 30).  
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This study used DHS LPR New Arrivals breakdown by calendar year and country of birth 
because medical screening data are available to DGMQ at present only for LPR New Arrivals 
not for AOS.  DHS data were used as the denominators for the immigrant part (denominators 
summed up immigrant and refugee arrivals) when calculating LTBI prevalence. 
 
U.S Department of State (DOS) refugee data 
Data of refugee arrivals, gender, age and country of nationality were requested and received by 
DGMQ from Worldwide Refugee Admissions Processing System (WRAPS) of DOS.  They 
were not publically available.  Yearbook of Immigration Statistics contains data (source is DOS) 
of refugee arrival by country of nationality, but no breakdowns by gender and age and not for 
calendar year (only for U.S. federal fiscal year October 1 to September 30).   
 
Country of nationality is important information for analyzing LTBI among refugees because for 
refugees country of birth may differ from country of nationality.  For example, many Burmese 
refugee were born in refugee camps in Thailand.  Their country of birth was Thailand while their 
country of nationality was Burma.  Many Bhutanese refugee were born in refugee camps in 
Nepal.  Their country of birth was Nepal while their nationality was Bhutan.  Many Somali 
refugees were born in refugee camps in Kenya.  Their country of birth was Kenya while their 
nationality was Somalia.  All these three nationalities were among top 16 arrival countries in this 
study. 
 
This study used WRAPS country of nationality.  WRAPS data were used as the denominators for 
the refugee part (denominators summed up immigrant and refugee arrivals) when calculating 
LTBI prevalence. 
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DGMQ Electronic Disease Notification (EDN) data 
This data system was developed by DGMQ and put in use in January 2006.  It is not publically 
available (available to immigrant and refugee receiving states).  It stores data collected in 
immigrant and refugee overseas medical examinations.  DOS approved local panel physicians 
conducted medical examinations and entered the data in DOS medical examination forms 
(MEDICAL EXAMINATION FOR IMMIGRANT OR REFUGEE APPLICANT, CHEST X-
RAY AND CLASSIFICATION WORKSHEET, VACCINATION DOCUMENTATION 
WORKSHEET, MEDICAL HISTORY AND PHYISICAL EXAMINATION WORKSHEET).  
These forms are made available to DGMQ.  DGMQ uses EDN to notify receiving states of the 
arrivals of all refugees and immigrants who had medical conditions along with their 
demographic and medical information collected by the DOS forms and stored in EDN.  Health 
Department of the receiving states are required to conduct follow-up medical evaluation of all 
refugees and immigrants with medical conditions (mainly TB conditions) and follow up on their 
medical treatment. 
 
This study used EDN LTBI data.  Because LTBI is a medical condition these data are captured 
for both refugees and immigrants.   
 
This study used EDN TB TI form type (2007 vs 1991 TB TI) data.  If form type data could not 
determine whether 2007 or 1991 TB TI was used for medical screening 
“CoverSheetNotAvailable” (if available then 2007 TB TI) and “TBClassID” variables in EDN 
were taken into account.    
16 
 
 
 
TB TI data are incomplete in EDN because for immigrants only those who had medical 
conditions were captured in EDN (refugees were supposed to be all captured in EDN).  What 
type of TB TI forms was used for immigrants who did not have medical conditions were 
unknown.  Considering that 2007 TB TI implementation was same or similar in one country this 
study took immigrant captured in EDN as a simple random sample to make the inference on this 
variable for the entire immigrant population.  
  
Using TB TI form type and other relevant data in EDN to estimate 2007 TB TI percentage could 
be more accurate than using 2007 TB TI start date (official start date for a country) because 
situations happened such as a country still used 1991 TB TI forms even after the 2007 TB TI 
start date, or used 2007 TB TI forms in a pilot program before the 2007 TB TI start date.  
 
WHO TB Incidence and Prevalence data  
WHO TB incidence rates (per 100 000 population per year) was not used in the data sets. It 
indicates whether test for TB/LTBI is required in immigrant and refugee overseas medical 
examinations (if incidence rates ≥20 in the country).  Incidence rates were above 20 or much 
higher than 20 for 14 out of 16 top arrival countries.  Only Jamaica’s rates were less than 20 (6.5 
in 2008, 6.6 in 2009-2012), therefore, tests for LTBI were not required.  Mexico’s rates were 20-
21 (20 in 2008-2009, 21 in 2010-2012). 
  
WHO TB prevalence rate (per 100 000 population) was used as a predictor in regression model.  
These data are publically available and were downloaded from WHO website [7]. 
17 
 
 
 
Match country names used by different data sources 
Country of origin is an important variable for this analysis.  DHS, DOS, EDN and WHO TB data 
used different names for a same country for a few countries.  For example, North Korea was 
“Korea, North”, in DHS and DOS data, “KOREA, DEM PEOPLE REP” in EDN data and 
“Democratic people’s Republic of Korea” in WHO TB data.  tblRegions table in DGMQ 
Information on Migrant Population (IMP) database listed a country with its DHS, DOS, EDN 
and WHO country names in one record for matching.  This study matched DHS, DOS, EDN and 
WHO country names in their data with their corresponding names in tblRegions and chose 
WRAPS_nationality (DOS country name) as the name for country of origin to categorize country 
correctly.  
 
Data analysis software 
Microsoft SQL Server 2008 was used to create study data sets.  DHS, DOS, EDN and WHO data were 
stored in Microsoft SQL Server 2008 databases.  SQL queries were written to retrieve data for the study 
data sets.   
 
SAS 9.3 (SAS Institute) was used for statistical analysis.  
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Chapter 4 
RESULTS 
LTBI prevalence 
Overall prevalence of all arrival Countries vs top 16 arrival countries 
Overall prevalence for all arrival countries and top 16 arrival countries were 6.30% and 8.76%, 
respectively (Table 3).  Prevalence of top 16 arrival countries was much higher than that of all 
arrival countries (199 countries). 
 
Table 3. LTBI Prevalence - All Arrival Countries vs Top 16 Arrival Countries 
  All Top 16 
Arrival 524147 358516 
LTBI 33045 31418 
LTBI Prevalence 
(%) 6.30 8.76 
 
 
Proportions of prevalence and arrivals of top 16 arrival countries in all arrival countries 
Top 16 arrival countries contributed to 68.40% (358516/524147) arrivals and 95.08% (31418/ 
33045) LTBI cases (Table 4).   
 
Table 4. Arrival and LTBI – Proportions of Top 16 Arrival Countries in All Arrival Countries 
  Top 16 
In Total Arrival (%) 68.40 
In Total LTBI (%) 95.08 
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Prevalence by year of all arrival countries vs top 16 arrival countries 
Prevalence of both all arrival countries and top 16 arrival countries showed an increasing trend 
over the study period 2008 -2012 (Table 5).  
 
Table 5. LTBI Prevalence by Year of All Arrival Countries vs Top 16 Arrival Countries 
Arrival 
Year 
  All Top 16 
Arrivals LTBI 
LTBI 
(%)   Arrivals LTBI 
LTBI 
(%) 
2008 104799 1259 1.20  70029 1245 1.78 
2009 107972 7356 6.81  75298 7247 9.62 
2010 111170 8521 7.66  76651 8227 10.73 
2011 98636 7576 7.68  67333 7073 10.50 
2012 101570 8333 8.20   69205 7626 11.02 
 
 
Prevalence of the top 16 arrival countries 
The top five prevalence countries were the Philippines (42.74%) Vietnam (9.35%) and Mexico 
(8.71%), Bhutan 8.31% and China (7.80%).  The lowest three prevalence countries were Jamaica 
(0.00%), Pakistan (0.26%) and El Salvador (0.37%) (Table 6).  
  
Table 6. LTBI Prevalence (in Descending Order) Top 16 Arrival Countries  
Rank in 
Total 
Arrivals 
Country 
of Origin 
Arrival LTBI 
LTBI 
Prevalence 
 (%) 
3 
The 
Philippines 33446 14296 42.74 
7 Vietnam 19325 1806 9.35 
1 Mexico 73305 6386 8.71 
11 Bhutan 13331 1108 8.31 
5 China 24271 1894 7.80 
4 Burma 24987 1888 7.56 
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16 Somalia 7363 454 6.17 
2 
Dominican 
Republic 50405 2421 4.8 
15 Ethiopia 9414 333 3.54 
8 Haiti 18873 314 1.66 
9 India 14392 175 1.22 
14 Bangladesh 10950 92 0.84 
6 Iraq 22112 179 0.81 
12 
El 
Salvador 11671 43 0.37 
13 Pakistan 11269 29 0.26 
10 Jamaica 13402 0 0.00 
 
 
Regression analysis on LTBI prevalence 
Regression model 
Multiple logistic regression model was built to assess the association between LTBI prevalence 
and its potential predictors.   
 
Response variable was LTBI prevalence.  It was calculated (LTBI/total year arrivals) and added 
to the study data set. 
 
Predictors were country of origin, female percentage, TB TI 2007 percentage and WHO TB 
prevalence. 
 
In addition, female less than 50 percent variable (set based on female percentage and added to 
the data set) and its interaction with female percentage variable were added to the regression 
model as potential predictors after the examination of Loess plot between female percentage and 
log LTBI prevalence (i.e., log odds or logit).  Female 50 percent was approximately a dividing 
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point.  The rate of logit LTBI prevalence increased more rapidly before this point than after this 
point (Figure 1) 
 
Figure 1. Loess plot female percentage vs logit LTBI prevalence 
 
 
Regression coefficient estimates 
Coefficient estimates (i.e., log odds or logit) from SAS output Analysis of Maximum Likelihood 
Estimates for country of origin predictor were significant (p<.0001) (all tests α = 0.05) for 14 out 
of 16 top arrival countries, and not significant for China (p=0.1166) and Jamaica (p=0.8296).  
Coefficient estimates for the predictors of female percentage, TB TI 2007 percentage, WHO TB 
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prevalence, female less than 50 percent and its interaction with female percentage were all 
significant (p<.0001).  
 
Odds ratio estimates 
Odds ratio estimates for country of origin showed that compared to Mexico, China (OR = 0.886, 
95% CI = 0.762, 1.031) was not significant (CI including 1) and all other countries were 
significant; the Philippines (OR = 2.437, 95% CI = 1.634, 3.633) had the highest odds of LTBI, 
which was 2.44 times of that of Mexico and the only country with higher odds of LTBI than 
Mexico; and Bangladesh (OR = 0.041, CI = 0.028, 0.06) had the lowest odds of LTBI, which 
was 4.1% of that of Mexico. 
 
Odd ratio estimate for TB TI 2007 percentage (OR = 1.042, 95% CI =1.041,1.044) was holding 
other variables in the model constant with one percent point increase in 2007 TB TI form usage 
the odds of detecting LTBI increased by 4.2%. 
 
Odd ratio estimate for WHO TB prevalence (OR = 8.983,  95% CI = 3.826, 21.093)  was holding 
other variables in the model constant with one per 100,000 increase in WHO TB prevalence the 
odds of LTBI increased by about 8 times.  
 
Odd ratio estimate for Female percent was holding other variables in the model constant, when 
female in arrivals was minority with one percent point increase of female percentage (OR = 
1.196, 95% CI = 1.161, 1.233) the odds of LTBI increased by 19.6%, and when female in 
arrivals was majority with one percent point increase of female percentage (OR = 1.045, 95% CI 
= 1.015, 1.077) the odds of LTBI increased by 4.5% (Table 7). 
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Table 7. Odds Ratio Estimates – Top 16 Arrival Countries 
Odds Ratio Estimates       
Effect 
Point 
Estimate 
95% Wald 
Confidence Limits 
CountryOfOrigin Bangladesh vs Mexico 0.041 0.028 0.06 
CountryOfOrigin Bhutan vs Mexico 0.375 0.299 0.472 
CountryOfOrigin Burma vs Mexico 0.295 0.194 0.448 
CountryOfOrigin China vs Mexico 0.886 0.762 1.031 
CountryOfOrigin Dominican Republic vs 
Mexico 0.394 0.364 0.426 
CountryOfOrigin El Salvador vs Mexico 0.13 0.096 0.176 
CountryOfOrigin Ethiopia vs Mexico 0.339 0.275 0.418 
CountryOfOrigin Haiti vs Mexico 0.13 0.099 0.169 
CountryOfOrigin India vs Mexico 0.225 0.173 0.292 
CountryOfOrigin Iraq vs Mexico 0.692 0.589 0.813 
CountryOfOrigin Jamaica vs Mexico <0.001 <0.001 >999.999 
CountryOfOrigin Pakistan vs Mexico 0.06 0.038 0.093 
CountryOfOrigin The Philippines vs Mexico 2.437 1.634 3.633 
CountryOfOrigin Somalia vs Mexico 0.267 0.174 0.411 
CountryOfOrigin Vietnam vs Mexico 0.684 0.571 0.82 
TI07Percent 1.042 1.041 1.044 
WHOTBPrevalencePerce 8.983 3.826 21.093 
 
Odds Ratio Estimates and Wald Confidence Intervals 
Label Estimate 
95% 
Confidence 
Limits 
FemalePercent at FemaleLessThan50Pct=1 1.196 1.161 1.233 
FemalePercent at FemaleLessThan50Pct=0 1.045 1.015 1.077 
 
Predicted probability 
Predicted probability was calculated by the regression model.  In general, predicted probability 
was close to the observed probability indicating that the predicting power of the regression 
model was relatively strong.    
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The observed probability plot (Figure 2) and predicted probability plot (Figure 3) showed 
similarities, which both showed that the Philippines, Vietnam and Mexico were the three 
countries with the highest LTBI prevalence, which were consistent with Table 6. 
 
Figure 2. Observed Probability                                    Figure 3. Predicted Probability 
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Chapter 5 
DISCUSSION AND CONCLUSION 
Discussion 
Applying epidemiologic triad framework to diagnosing and treating LTBI would help address 
the issue in a more systematic and holistic way. 
 
Agent – LTBI and its interdependence with the host and the environment 
As described chapter 1 and 2, TB and LTBI are related.  TB is infectious and the mode of 
transmission is droplet spread.  LTBI is asymptomatic and not infectious.  But LTBI can 
progress to TB (reactivation TB), and the host becomes sick and infectious [1] [8]. 
In general, the chance of reactivation TB is low (5-10%) [8] [15] [21].  This makes the disease 
easily live in the body of the host without detected and not being dealt with properly by the host 
and the environment [24] [26] [27]. 
 
Host – Immigrant and refugee children resettled in the U.S. and their interdependence with the 
agent and the environment 
Development of LTBI and reactivation TB depends on the immunity, age and environment of the 
host.  Studies found that the risk of reactivation TB was higher for young children, persons with 
HIV-infections or other particular medical conditions [8] [13] [15].  If infected infants and 
children aged under 4 years could frequently progress to miliary TB or TB meningitis.  
Adolescence could progress to adult-type TB.   
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Studies also found that the risk of reactivation TB was substantially higher among foreign-born 
person and reactivation TB contributed a large proportion to the TB cases in the U.S. [3] [4] [22].  
This study demonstrated top 16 arrival countries contributed largely to arrivals (68%) and greatly 
to LTBI cases (95%) (Table 4).  LTBI prevalence of all arrival countries and top 16 arrival 
countries showed an increasing trend in 2008-2012 (Table 5).  These LTBI could add to the pool 
of TB case in the U.S. due to reactivation TB. 
 
Environment – country of origin and resettlement country and their interdependence with the 
host 
High prevalence of TB in country of origin was the major source of LTBI among the immigrants 
and refugees resettled in the U.S.  According to CDC report Mexico, the Philippines, India, 
Vietnam, and China were the top five countries of origin of foreign-born persons with TB in the 
U.S. in 2013 [2].  This study showed the top five countries of origin of LTBI prevalence were the 
Philippines, Vietnam, Mexico, Bhutan and China. The similarity of these two sets of results 
indicated the close relationship.  This was also found by this study.  WHO TB prevalence 
predictor had the highest odds ratio (OR = 8.983, 95% CI = 3.826, 21.093) among all the predictors.  
A study found that TB was the most significant predictor of LTBI [17].  Another study pointed 
out the source that causes TB infection for most children was close contact with adult TB cases 
[27].   
 
The host was affected by the agent and the environment of the country of origin, and in turn they 
impacted the environment of the country in which they resettled.  The host was also affected by 
the environment of the resettlement country.  Actions should be taken to avert the negative 
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impacts of agent, host and environment.  Progress has been made.  The TB death rate dropped 
45% between 1990 and 2013 [11].  Awareness of the importance of diagnosing and treating 
LTBI has increased tremendously.  Current LTBI treatment guideline published by CDC in 2011 
called treating LTBI “a cornerstone of the U.S. strategy for TB elimination” [20].  Many studies 
pointed out the imperativeness of treating LTBI among foreign-born persons and its public 
health and economic benefits [3] [4] [22], and also suggested targeted testing and treatment 
based on risk factors [13] [15] [16] [17] [18].  IGRA as a new TB/LTBI test method overcame 
some limitations of the convention test method [13] [25], though more clinical trials are needed 
[13] and the cost is a concern [21].  Clinical trials indicated that treating LTBI with INH for 6 to 
12 month could result in 69% to 93% reduction of TB [24].   Shortened treatment regimen with 
INH and rifapentine (RPT) weekly for 12 weeks under directly observed therapy (DOT, i.e., give 
patients the medicine and observe them taking the medicine) was proved by clinical trials as 
effective as the U.S. standard regimen with INH daily for 9 month without DOT, and has been 
recommended by CDC since 2011 for LTBI treatment [20].  WHO has similar recommendations 
[21].  Better access to medical services, more knowledge of the disease, social support, 
assistance in finding transportation, housing, education and employment opportunities can help 
host overcome culture barriers, fear and stigma about the disease and being willing to be tested 
and complete the treatment. 
 
2007 TB TI has led the way in addressing the challenges posed by the agent, the host and the 
environment.  It requires DOT, and culture test.  It also requires that children aged 2-14 years 
from high TB prevalence countries or having contact with TB or symptoms of TB to have 
TST/IGRA test to detect TB/LTBI.  This study showed that 2007 TB TI was effective in 
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detecting LTBI (OR = 1.042, 95% CI =1.041, 1.044).  Under 1991 TB TI medical screening for 
children younger than 15 only limited to symptom review, TST or IGRA tests was required only 
for children with symptoms. Culture test was not required, so smear-negative but culture positive 
TB could not be detected [28].  DOT helps increase drug adherence and the completion of 
TB/LTBI treatment.  2007 TB TI requires immigrant and refugee children who diagnosed with 
LTBI to have preventive therapy, but in general treatment should not be started until the arrival 
in the U.S.  This treatment specification also applies to immigrant and refugees who had TB but 
completed required treatment, and tests of sputum smears and cultures were all negative.  They 
can travel to the U.S. and continue their treatment after the arrival.  Treatment status should be 
documented to expedite follow-up medical evaluation upon the arrival in the U.S. [5].  These 
specifications put heavy responsibility on receiving states to ensure the completion of treatment.  
This is also reflected in the new perspective in the U.S. TB control strategy as stated in 
ATS/CDC guidelines for treatment of TB “The responsibility for successful treatment is clearly 
assigned to the public health program or private provider, not to the patient” [19]. 
 
Receiving states are required to conduct follow-up medical evaluation on the immigrants and 
refugees arrived in their states.  DGMQ uses Electronic Disease Notification (EDN) to notify 
states of the arrivals of all refugees and immigrants with medical conditions whose overseas 
medical examination data are stored in EDN.  Receiving state health department and local health 
clinics have access to EDN.  Follow-up evaluation includes TST or IGRA test, chest radiograph 
(CXR) and other tests and examination.  Data of follow-up evaluation are stored in EDN. 
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In fiscal year 2013 (October 1, 2012 - September 30, 2013), the top five states (ranking by EDN 
notifications) and their follow-up evaluation percentage out of the total arrivals in the state were 
California (73%), Texas (69%), New York (79%), Florida (71%) and Illinois (62%).  The states 
with the highest and lowest follow-up percentage were Minnesota (92%) and Hawaii (60%), 
respectively.  These numbers indicate that states should address their follow-up gaps to ensure 
the completion of TB/LTBI treatment. 
 
Strength of the study 
This study has strength.  It took advantage of the data resources of DGMQ and combined 
immigrant and refugee arrival and LTBI data and conducted descriptive and analytic analysis.  
Most of the LTBI data were collected after 2007, therefore, this is an area lack of study. 
 
Limitations of the study 
This study has limitations.  As described in data source section, type of TB TI forms used for 
immigrants who did not have medical conditions were unknown.  Inferences were made.  Age 
was no stratified by age groups due to no further breakdown under 2-14 age group for 
immigrants in DHS data.  
 
Recommendations for future studies 
Continue this study.  2007 TB TI has been implemented in almost all panel sites worldwide since 
October 2013.  More LTBI data will be collected.  More studies need to be conducted on 
prevalence and risk factors of LTBI among immigrant and refugee population, which may help 
future interventions. 
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Conclusions Diagnosing and treating LTBI and continuing the battle against TB globally are 
critical to TB elimination in the U.S.  2007 TB TI has contributed to detecting LTBI cases, 
should be implemented vigorously in immigrant and refugee overseas medical screening.  
Receiving states should address their follow-up gaps to ensure the completion of TB/LTBI 
treatment.  Resources need to be allocated properly to states with high TB/LTBI burden. 
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